Biogen’s Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

June 17, 2021 Auto Bot Biogen, Clinical Trials, P-II, Primary Endpoint 0

Shots:

  • The P-II TANGO study evaluating the safety & efficacy of gosuranemab vs PBO in 654 patients aged 50–80 yrs with MCI due to AD or with mild AD for 78 wks across 97 sites, followed by a dose-blind long term extension period
  • The trial did not meet its 1EPs i.e change from baseline on CDR-SB @ 78 wks., no treatment benefit was observed on exploratory efficacy EPs includes ADAS-Cog 13, ADCS-ADL, MMSE & FAQ. Additionally, the therapy was well-tolerated overall & safety outcomes were consistent with previous studies of gosuranemab
  • The company has decided to discontinue the further clinical development of gosuranemab while investigation of additional data include CSF biomarkers are ongoing

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: The Business Journals

The post Biogen’s Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease first appeared on PharmaShots.